Showing 5631-5640 of 9797 results for "".
- Let There Be Light: Lumohs Founder Donates Scalpels to Floating Doctorshttps://practicaldermatology.com/news/let-there-be-light-lumohs-founder-donates-scalpels-to-floating-doctors/2461595/Floating Doctors will be using the Lumohs scalpel when treating underserved patients in areas without electricity or water. The Floating Doctors' volunteer medical teams deploy by boat, packhorse, or on foot to remote underserved areas. The Lumohs is a pate
- BTL Takes a Stand Against Illegal and Counterfeit Aesthetic Deviceshttps://practicaldermatology.com/news/btl-takes-a-stand-against-illegal-and-counterfeit-aesthetic-devices/2461593/BTL is making inroads in its efforts to safeguard medical providers and consumers from counterfeit devices in the United States through legal action and the seizure of illegally imported devices at the border. BTL has filed court documents stating that defendants use and sell knock
- Study: Lycomato Carotenoid Supplement May Boost Skin Health and Appearancehttps://practicaldermatology.com/news/study-lycomato-carotenoid-supplement-boost-skin-health-and-appearance/2461592/Daily supplementation with Lycomato may improve fine lines, wrinkles, pore appearance brightness/radiance, skin tone evenness, dark spot intensity, smoothness, and firmness after four weeks of use, according to a new study&
- Fewer Cases of Melanoma, Cancers in Extracutaneous Sites Seen in Patients with Atopyhttps://practicaldermatology.com/news/fewer-cases-of-melanoma-cancers-in-extracutaneous-sites-seen-in-patients-with-atopy/2461591/Fewer cases of melanoma are observed in people with a history of atopic diseases, such as allergic asthma or rhinitis, than in nonatopic people, according to a new study in Melanoma Research. Specifically, the risk of melanoma in people with atopy was up to 50% lower than
- U.S. FDA: Renuvion Cleared to Coagulate and Contract Soft Tissues, Including Subcutaneous Tissuehttps://practicaldermatology.com/news/us-fda-renuvion-cleared-to-coagulate-and-contract-soft-tissues-including-subcutaneous-tissue/2461590/The U.S. Food and Drug Administration (FDA) has cleared the use of the Renuvion APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. (Soft tissue includes subcutaneous tissue.) “We are pleas
- Cetaphil Unveils Digital AI Skin Analysis Toolhttps://practicaldermatology.com/news/cetaphil-unveils-digital-ai-skin-analysis-tool/2461587/Cetaphil is launching Cetaphil AI Skin Analysis, a comprehensive skin analyzer off
- Candela Announces Health Canada Licences for Nordlys Multi-Application System and Frax Pro Devicehttps://practicaldermatology.com/news/candela-announces-health-canada-licences-for-nordlys-multi-application-system-and-frax-pro-device/2461586/Candela announced Health Canada licensing and the availability of the Nordlys multi-application platform, which features Selective Waveband Technology (SWT) and the dual-wavelength Frax Pro non-ablative fractional laser platform.[1-4] The Nordlys is designed to improve treatme
- Dyskerin May Signal When SCC Is On The Movehttps://practicaldermatology.com/news/dyskerin-may-signal-when-scc-is-on-the-move/2461585/The protein dyskerin may provide important clues as to how cutaneous squamous cell carcinoma tumors prepare themselves to migrate to the lymph nodes to metastasize other organs, a new study suggests. These cells stop consuming glucose so that they can survive by using LDL chol
- Coral-friendly Sunscreen Provides Better UV Protection Than Existing Optionshttps://practicaldermatology.com/news/coral-friendly-sunscreen-provides-better-uv-protection-than-existing-options/2461584/A new coral-friendly polymeric UV filter may be more effective at preventing sunburn than existing sunscreens. Researchers used polymerization to create large molecules that still block UV radiation but are too big to penetrate our skin, coral, and algae. The study was p
- Bristol Myers Squibb Advances Melanoma Drug Candidate Opdivo in US and Europehttps://practicaldermatology.com/news/bristol-myers-squibb-advances-melanoma-drug-candidate-opdivo-in-us-and-europe/2461583/Bristol Myers Squibb announced that the FDA has accepted the supplemental Biologics License Application (BLA) for Opdivo (nivolumab) as monotherapy in the adjuvant setting for the treatment of patients with completely resected stage IIB or IIC melanoma. The company also announced t